Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen

Pulse Biosciences has initiated a new $59.98 million at-the-market equity program with TD Cowen to sell common stock, providing flexible access to capital. This new arrangement replaces a previous ATM program, terminated on February 18, 2026, which still had unused capacity. Sales under the new program can occur on The Nasdaq Capital Market or other permitted methods at market or negotiated prices.